CPHI 2026: Moderna links COVID-era manufacturing lessons to current drug product work with CDMOs

Moderna used the 2026 edition of CPHI, a major global event for pharmaceutical manufacturing, to focus on a topic that goes beyond vaccines and into the mechanics of making medicines at scale. In comments carried by Yahoo Finance, the company’s VP of Drug Product Operations, Michelle Rodriguez, discussed how Moderna is building on manufacturing experience from its COVID-era ramp to support current and future drug product operations, including the way it partners with external manufacturing providers.

The segment centered on Moderna’s relationship model for drug product, where the company relies on contract development and manufacturing organizations, or CDMOs. CDMOs are specialist manufacturers that take on elements of drug development and production, allowing sponsors like Moderna to scale output or add capabilities without running every step entirely in-house. Moderna’s message at CPHI was that those partnerships require operational discipline and lessons learned during periods of intense manufacturing demand.

Rodriguez’s remarks, as summarized in the coverage, emphasized how Moderna approaches execution and coordination with CDMOs rather than framing manufacturing capacity as an abstract goal. The focus was on “drug product operations,” a term that generally refers to the end-to-end activities needed to produce a finished pharmaceutical product, including manufacturing planning, batch execution, quality controls, and other operational steps that turn raw materials and processes into deliverable medicines.

A recurring theme in the CPHI framing was that Moderna’s COVID-era production experience created institutional know-how that still matters. The company’s view, as presented in the coverage, is that earlier manufacturing cycles inform how it works with partners now, including how processes are designed and how operational expectations are set. In a sector where supply chain performance and manufacturing consistency can strongly affect timelines, the ability to convert past experience into ongoing operating practices is a concrete advantage.

While the coverage points to Moderna’s work with CDMOs, it did not provide details on specific contract manufacturers, the scope of outsourced steps, or any changes to supplier strategy. It also did not disclose whether Rodriguez discussed particular product programs, batch release metrics, technology transfers, or new manufacturing platforms. For editorial review, those omissions are important because they limit what can be responsibly inferred about the company’s near-term operational footprint or incremental costs.

Moderna’s broader sector context underscores why these discussions carry weight even when financial figures are not in view. The market for biologics and advanced therapies has made manufacturing expertise a competitive factor, and many biopharmaceutical companies manage a hybrid model that combines internal capabilities with specialized CDMOs. In that environment, companies that can operationalize learnings from disruption or rapid scaling tend to look for repeatable partner workflows, clearer quality alignment, and more predictable execution.

Still, the record from this CPHI-linked item is limited. The coverage indicates that Rodriguez addressed how Moderna applies COVID-era manufacturing lessons and works with CDMOs, but it does not provide a transcript, direct quotations, or deeper technical specifics that would allow an audit of the claims. As a result, readers should treat the discussion as high-level operational messaging rather than evidence of quantified performance improvements or new contractual arrangements.

Looking ahead, what to watch is whether Moderna expands on the same themes in more detailed public disclosures, such as investor materials, technical conference presentations with published slides, or regulatory filings that describe process changes and manufacturing capacity commitments. For industry observers, the practical question is how lessons from emergency-scale production translate into measurable improvements in cycle times, quality consistency, and partner integration across the drug product lifecycle. If Moderna provides those particulars, it will offer a clearer bridge from conference-level messaging to operational outcomes.